Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats.


Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 19 07 2021
accepted: 01 11 2021
pubmed: 3 3 2022
medline: 9 6 2022
entrez: 2 3 2022
Statut: ppublish

Résumé

Ketamine and psilocybin belong to the rapid-acting antidepressants but they also produce psychotomimetic effects including timing distortion. It is currently debatable whether these are essential for their therapeutic actions. As depressed patients report that the "time is dragging," we hypothesized that ketamine and psilocybin-like compounds may produce an opposite effect, i.e., time underestimation, purportedly contributing to their therapeutic properties. Timing was tested following administration of (R)- and (S)-ketamine, and psilocybin, psilocin, and norpsilocin in the discrete-trial temporal discrimination task (TDT) in male rats. Timing related to premature responses, and cognitive and unspecific effects of compounds were tested in the 5-choice serial reaction time task (5-CSRTT) in the standard 1-s, and "easier" 2-s stimulus duration conditions, as well as in the vITI variant promoting impulsive responses. (S)-ketamine (15 but not 3.75 or 7.5 mg/kg) shifted psychometric curve to the right in TDT and reduced premature responses in 5-CSRTT, suggesting expected time underestimation, but it also decreased the accuracy of temporal discrimination and increased response and reward latencies, decreased correct responses, and increased incorrect responses. While (R)-ketamine did not affect timing and produced no unspecific actions, it reduced incorrect responses in TDT and increased accuracy in 5-CSRTT, suggesting pro-cognitive effects. Psilocin and psilocybin produced mainly unspecific effects in both tasks, while norpsilocin showed no effects. Time underestimation produced by (S)-ketamine could be associated with its antidepressant effects; however, it was accompanied with severe behavioral disruption. We also hypothesize that behavioral disruption produced by psychedelics objectively reflects their psychotomimetic-like actions.

Identifiants

pubmed: 35234983
doi: 10.1007/s00213-021-06020-5
pii: 10.1007/s00213-021-06020-5
pmc: PMC9166826
doi:

Substances chimiques

Antidepressive Agents 0
omega-N-methyl-4-hydroxytryptamine 0
Psilocybin 2RV7212BP0
Serotonin 333DO1RDJY
Ketamine 690G0D6V8H
psilocin CMS88KUW0G

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1689-1703

Informations de copyright

© 2022. The Author(s).

Références

Psychopharmacology (Berl). 2002 Oct;163(3-4):362-80
pubmed: 12373437
Behav Pharmacol. 2010 Feb;21(1):11-20
pubmed: 19949322
Trends Pharmacol Sci. 2009 Nov;30(11):563-9
pubmed: 19837463
J Nat Prod. 2020 Feb 28;83(2):461-467
pubmed: 32077284
Schizophr Bull. 2018 Jan 13;44(1):54-64
pubmed: 28525601
Neuropharmacology. 2016 Aug;107:364-375
pubmed: 27020041
Eur Neuropsychopharmacol. 2020 Nov;40:4-16
pubmed: 33004229
Eur Neuropsychopharmacol. 2013 Nov;23(11):1414-22
pubmed: 23561394
Acta Neuropsychiatr. 2019 Aug;31(4):213-219
pubmed: 31106729
Br J Psychiatry. 2006 Aug;189:173-9
pubmed: 16880489
Behav Neurosci. 2011 Oct;125(5):764-74
pubmed: 21942437
Physiol Behav. 1992 Mar;51(3):493-9
pubmed: 1523226
J Psychopharmacol. 2016 Dec;30(12):1181-1197
pubmed: 27909165
PLoS One. 2014 Dec 19;9(12):e115374
pubmed: 25526617
Psychopharmacology (Berl). 2016 Oct;233(19-20):3513-25
pubmed: 27534540
Mol Psychiatry. 2021 Nov;26(11):6704-6722
pubmed: 33859356
Pharmacol Biochem Behav. 2006 Sep;85(1):114-22
pubmed: 16920182
Eur J Pharmacol. 1990 Aug 21;185(1):1-10
pubmed: 2171955
Behav Pharmacol. 1997 Aug;8(4):293-308
pubmed: 9832989
Curr Pharm Des. 2018;24(22):2556-2563
pubmed: 30058481
Arch Gen Psychiatry. 2006 Aug;63(8):856-64
pubmed: 16894061
Nat Commun. 2020 Dec 22;11(1):6431
pubmed: 33353946
Lancet Psychiatry. 2019 Dec;6(12):975-977
pubmed: 31680013
Front Pharmacol. 2021 Feb 26;12:640241
pubmed: 33716753
Eur Neuropsychopharmacol. 2014 Aug;24(8):1381-93
pubmed: 24846536
Psychopharmacology (Berl). 2010 Jun;210(2):263-74
pubmed: 20358363
Eur Arch Psychiatry Clin Neurosci. 2021 Apr;271(3):577-582
pubmed: 32078034
J Psychopharmacol. 2007 Jan;21(1):50-64
pubmed: 16714323
Pharmacol Biochem Behav. 2020 Oct;197:173011
pubmed: 32758523
Pharmacol Rev. 1995 Jun;47(2):235-53
pubmed: 7568327
Elife. 2015 Dec 07;4:
pubmed: 26641377
J Exp Psychol Anim Behav Process. 1983 Apr;9(2):171-201
pubmed: 6842136
Lancet Psychiatry. 2016 Jul;3(7):619-27
pubmed: 27210031
Psychopharmacology (Berl). 2011 Sep;217(2):255-69
pubmed: 21484239
Anesthesiology. 1982 Apr;56(4):291-7
pubmed: 6278991
J Affect Disord. 2015 Apr 1;175:359-72
pubmed: 25665496
J Exp Psychol Anim Behav Process. 1981 Jan;7(1):18-30
pubmed: 7229573
Biol Psychiatry. 2000 Feb 15;47(4):351-4
pubmed: 10686270
Psychopharmacology (Berl). 1999 Oct;146(4):348-61
pubmed: 10550486
J Psychopharmacol. 2016 Dec;30(12):1165-1180
pubmed: 27909164
Psychopharmacology (Berl). 1983;79(1):10-5
pubmed: 6403957
Behav Pharmacol. 2006 Feb;17(1):51-9
pubmed: 16377963
Brain Res. 1984 Feb 27;294(1):174-7
pubmed: 6199090
Biol Psychiatry. 2010 Jul 1;68(1):5-16
pubmed: 20488434
Psychol Sci. 2012 Aug 1;23(8):879-86
pubmed: 22760888
J Nat Prod. 2003 Jun;66(6):885-7
pubmed: 12828485
Arch Gen Psychiatry. 1994 Mar;51(3):199-214
pubmed: 8122957
Biol Psychiatry. 2007 Sep 15;62(6):687-93
pubmed: 17343834
Psychopharmacology (Berl). 2009 Jul;204(4):679-92
pubmed: 19263039
Swiss Med Wkly. 2007 Apr 21;137(15-16):215-6
pubmed: 17525875
Eur J Clin Pharmacol. 2002 Feb;57(12):869-75
pubmed: 11936706
Eur Neuropsychopharmacol. 1997 Feb;7(1):25-38
pubmed: 9088882

Auteurs

Piotr Popik (P)

Behavioral Neuroscience and Drug Development, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343, Kraków, Poland. nfpopik@cyf-kr.edu.pl.

Adam Hogendorf (A)

Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343, Kraków, Poland.

Ryszard Bugno (R)

Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343, Kraków, Poland.

Shaun Yon-Seng Khoo (SY)

Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.

Pawel Zajdel (P)

Department of Organic Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-383, Kraków, Poland.

Natalia Malikowska-Racia (N)

Behavioral Neuroscience and Drug Development, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343, Kraków, Poland.

Agnieszka Nikiforuk (A)

Behavioral Neuroscience and Drug Development, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343, Kraków, Poland.

Joanna Golebiowska (J)

Behavioral Neuroscience and Drug Development, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343, Kraków, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH